Hoth Therapeutics, Inc. (NASDAQ: HOTH) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development, and testing of new therapeutics to treat unmet medical needs. Shares of the biopharma company are surging 97% through early trading on Tuesday, January 4, 2022. Over the past three months, Hoth Therapeutics has seen an average daily volume of 277,970 shares. However, volume of 134.51 million shares or dollar volume of around $182.93 million, has already exchanged hands through early trading on Tuesday.
Shares of Hoth Therapeutics are soaring after the company announced its HT-ALZ therapeutic has demonstrated positive results for the treatment of Alzheimer’s Disease in mouse models. Specifically, HT-ALZ showed a significant decrease in amyloid β in the Alzheimer’s Disease research.
As a result, the proof-of-concept data demonstrates support for HT-ALZ as a potential new therapeutic that is capable of modifying A β plaque formation in the brain. The research was conducted as a part of Hoth Therapeutics’ Sponsored Research Agreement with Washington University in St. Louis.
Alzheimer’s is a neurodegenerative disease that features aggregates of amyloid β plaque and neurofibrillary tangles of Tau protein in the brain. These aggregates contribute to clinical symptoms of Alzheimer’s, such as dementia.
“The overall positive result from these studies is a first step but a big one in the development of HT-ALZ as an Alzheimer’s therapeutic,” said Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics, Inc. “HT-ALZ is a unique therapeutic in the AD development space because it is eligible for streamlined development under the 505(b)(2) pathway, including available safety data. This allows Hoth to reach efficacy clinical trials faster and bring a new potential treatment for patients with Alzheimer’s disease.”
Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article, but may choose to initiate a position at any time. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.